Published online before print June 20, 2005, doi: 10.1161/01.HYP.0000172756.41375.e4
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2005;46:267.)
© 2005 American Heart Association, Inc.
Editorial Commentaries |
More Evidence of Cardiorenal Protective Effects of Peroxisome Proliferator-Activated Receptor Activation
From the CIHR Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada.
Correspondence to Ernesto L. Schiffrin, MD, PhD, FRCPC, Clinical Research Institute of Montreal, 110 Pine Ave W, Montreal, Quebec, Canada H2W 1R7. E-mail ernesto.schiffrin{at}ircm.qc.ca
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that heterodimerize with the retinoid X receptor and modulate functions of many target genes. Three PPARs, 
, ß/
, and 
, have been demonstrated. PPAR is involved in fatty acid oxidation and expressed in liver, kidney, and skeletal muscle; PPARß/ is ubiquitous and regulates lipid metabolism; and PPAR plays a role in fat cell differentiation, lipid storage, and insulin sensitivity.1 PPARs are present in cardiovascular tissues, including the endothelium, smooth muscle cells, macrophages, and the heart.2–4 Fibrates (hypolipemic agents) and fatty acids activate PPAR, and thiazolidinediones or glitazones (antidiabetic drugs) stimulate PPAR.5 However, the endogenous ligands of PPARs remain unknown.
PPAR and PPAR have increasingly been demonstrated to exert cardiovascular protective effects, independent of their metabolic actions.3,4 Whereas metabolic effects of PPARs are mediated by activation of a PPAR-responsive element present in the promoter region of different genes, the cardiovascular protective actions may result from anti-inflammatory and antioxidant actions mediated by transrepression of proinflammatory and pro-oxidant genes. PPAR activators lowered blood pressure, induced favorable effects on the heart, and corrected vascular structure and endothelial dysfunction in several rodent models of hypertension, including genetic models,6 angiotensin II,7–9 and endothelin-1 (ET-1)–dependent hypertension.10 These effects were associated with antioxidant, anti-inflammatory, antiproliferative, antihypertrophic, and antifibrotic effects.11 Different studies have demonstrated as well that activation of PPAR exerts antiatherosclerotic actions.12 PPAR, through its effect to lower triglycerides as well as its anti-inflammatory action, also prevents progression of atherosclerosis.13 We3,4 and others have proposed that activators of PPARs may become therapeutic agents useful in the prevention of cardiovascular disease beyond their effects on carbohydrate and lipid metabolism.
In this issue of Hypertension, Williams et al14 demonstrate that the PPAR activator clofibrate reduced blood pressure in salt-dependent hypertension during endothelin B (ETB) receptor blockade. ETB receptors have been demonstrated to exert a natriuretic function along different nephron segments in vitro and in vivo in rodents. Gene knockout of the ETB receptor with rescue of extrarenal ETB receptors results in blood pressure elevation in mice,15 presumably the result, at least in part, of decreased natriuresis, although the hypertension has also been attributed to increased circulating ET-1 impacting on ETA receptors.16 Interestingly, in humans, the natriuretic effect of ETB receptors appears to be minor.17 ETB receptor-induced natriuresis is, in part, mediated by inhibition of the sodium epithelial channel. The mechanisms whereby ETB receptors signal to the epithelial channel appear to include cylooxygenase activation and prostaglandin E2 formation. In addition, in vitro and in vivo studies suggest that cytochrome P450 4A (CYP4A) activation and 20-HETE may be mediators of ETB-induced natriuresis.18 Recently, increased production of 20-HETE in the kidney was shown to participate in the blood pressure–lowering effects of fenofibrate, another PPAR activator, in angiotensin II–induced hypertension in mice.19 Williams et al14 extend these observations by demonstrating that PPAR regulates the activation of CYP4A and generation of 20-HETE. This results in an increased natriuresis that counteracts the ETB receptor antagonist-induced anti-natriuresis. In this model of sodium-dependent hypertension, the natriuretic effect of 20-HETE lowers blood pressure. Interestingly, 20-HETE has seemingly opposed actions to induce natriuresis20 and cause vasoconstriction.21 In the present paradigm, the natriuretic effect is the predominant one. PPAR activation thus lowers blood pressure in this model by enhancing an ET-1–mediated action. In another model of salt-sensitive hypertension, the deoxycorticosterone acetate–salt rat, PPAR activation reduced prepro–ET-1 expression in the vasculature and contributed to cardiovascular protection, albeit without a major degree of blood pressure lowering.10 This underlines the dual actions of ET-1 through renal (natriuretic) and vascular ETA (constrictor) and ETB receptors (smooth muscle constrictor and endothelial dilator) and those of 20-HETE (natriuretic and constrictor actions). It also underlines that PPAR activators that exert cardiovascular and renal protective actions via their metabolic effects do so also through their pleiotropic effects at different levels. A caveat that should be noted is that some of these effects present in rodents may not occur in humans, as mentioned for ETB-induced natriuresis17 or for PPAR-induced blood pressure lowering, which has not been observed with fibrates.
In summary, by different mechanisms, PPAR activators ( in this and other studies and in other reports) are able to exert cardiovascular and renal protective actions. With the advent of the new dual PPAR/ agonists, there is promise that cardiovascular and renal protection may be achieved in a variety of cardiovascular conditions. The mechanisms for these cardiorenal protective actions, as demonstrated in part by the work of Williams et al,14 are only starting to be revealed.
 |
Acknowledgments |
|---|
This work was supported by grants 13570 and 37917 and a group grant to the Multidisciplinary Research Group on Hypertension, all from the Canadian Institutes of Health Research (CIHR).
|
Footnotes |
|---|
The opinions expressed in this editorial commentary are not necessarily those of the editors or of the American Heart Association.
|
References |
|---|
 Top References |
|---|
1. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-
, -ß, and - in the adult rat. Endocrinology. 1996; 137: 354–366.[Abstract]2. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 2000; 129: 823–834.[CrossRef][Medline] [Order article via Infotrieve]
3. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferators-activated receptors: vascular and cardiac effects in hypertension. Hypertension. 2003; 42: 664–668.
4. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol. 2005; 288: H1037–H1043.
5. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994; 91: 7355–7359.
6. Diep QN, Amiri F, Benkirane K, Paradis P, Schiffrin EL. Long-term effects of PPAR activator pioglitazone on cardiac hypertrophy and inflammation in SHRSP. Can J Physiol Pharmacol. 2004; 82: 976–985.[Medline]
[Order article via Infotrieve]
7. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-. Circulation. 2002; 105: 2296–2302.
8. Diep QN, Amiri F, Touyz RM, Cohn JS. Endemann D, Schiffrin EL. PPAR activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002; 40: 866–871.
9. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL. PPAR activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol. 2004; 36: 295–304.[CrossRef][Medline]
[Order article via Infotrieve]
10. Iglarz M, Touyz RM, Amiri F, Lavoie M-F, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor- and – activators on vascular remodeling in endothelin-dependent hypertension. Arterioscl Thromb Vasc Biol. 2003; 23: 45–51.
11. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-
B and AP-1. J Biol Chem. 1999; 274: 32048–32054.
12. Ishibashi M, Egashira K, Hiasa Ki, Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T, Takeshita A. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension. 2002; 40: 687–693.
13. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome Proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004; 94: 1168–1178.
14. Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM. Peroxisome proliferator-activated receptor–alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension. 2005; 46: 366–371.
15. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest. 2000; 105: 925–933.[Medline] [Order article via Infotrieve]
16. Elmarkaby AA, Loomis ED, Pollock JS, Pollock DM. ETA receptor blockade attenuates hypertension and decreases reactive oxygen species in ETB receptor deficient rats. J Cardiovasc Pharmacol. 2004; 44: S7–S10.[CrossRef][Medline] [Order article via Infotrieve]
17. Kaasjager KA, Koomans HA, Rabelink TJ. Endothelin-1-induced vasopressor responses in essential hypertension. Hypertension. 1997; 30: 15–21.
18. Escalante BA, McGiff JC, Oyekan AO. Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule. Am J Physiol. 2002; 282: F144–F150.
19. Vera T, Taylor M, Bohman Q, Flasch A, Roman RJ, Stec DE. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension. 2005; 45: 730–735.
20. Alonso-Galicia M, Frohlich B, Roman RJ. Induction of P450A4 activity improves pressure-natriuresis in Dahl S rats. Hypertension. 1998; 31: 232–236.
21. Ma YH, Gebremedhin D, Schwartzman ML, Falck JR, Clark JE, Masters BS, Harder DR, Roman RJ. 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ Res. 1993; 72: 126–136.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||